Advertisement

Recent Advances in the Management of Islet Cell Tumors

  • Paul N. Maton
Part of the Topics in Gastroenterology book series (TGEN)

Abstract

Islet cell tumors are relatively rare. They can occur as a sporadic disease and most of them have also been described as part of multiple endocrine neoplasia type 1. One of the best available estimates of frequency of the occurrence of these tumors comes from Ireland where the incidence of insulinomas is 0.9 case per million per year, gastrinomas 0.4 cases, and all other islet cell tumors less than 0.2 case per million per year.1 Islet cell tumors are usually described as slow growing and some patients with extensive metastatic disease live for many years. Nevertheless, many of these tumors release biologically active products into the circulation that can produce symptoms out of all proportion to tumor bulk. Indeed, these symptoms may be life threatening in a patient who otherwise has a relatively good prognosis from the point of view of tumor growth and spread. Conversely, the abolition of paraneoplastic symptoms can leave the patient feeling well despite the presence of a considerable tumor burden.

Keywords

Gastric Acid Secretion Multiple Endocrine Neoplasia Type Islet Cell Tumor Growth Hormone Release Factor Plasma Gastrin 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Buchanan KD, Johnston CF, O’Hare MMT, Ardill JES, Shaw C, Collins JSA, Watson RCP, Atkinson AB, Hadden DR, Kennedy TL, Sloan JM. Neuroendocrine tumors: A European view. Am J Med 1986; 81 Suppl 6B:14–22.PubMedGoogle Scholar
  2. 2.
    Ch’ng JLC, Polak JM, Bloom SR. Miscellaneous tumors of the pancreas. In: The Exocrine Pancreas: Biology, Pathobiology and Diseases (Go VLW, Gardner JD, Brooks FP, Lebenthal E, DiMagno EP, Scheele GA, eds). New York: Raven Press, 1986, pp. 763–771.Google Scholar
  3. 3.
    Maton PN, Gardner JD, Jensen RT. The incidence and etiology of Cushing’s syndrome in Zollinger-Ellison syndrome. N Engl J Med 1986;315:1–5.PubMedCrossRefGoogle Scholar
  4. 4.
    Clissold SP, Campoli-Richards DM. Omeprazole: A preliminary review of the pharmacodynamic and pharmacokinetic properties, and therapeutic potential in peptic ulcer disease and Zollinger-Ellison syndrome. Drugs 1986;32:15–47.PubMedCrossRefGoogle Scholar
  5. 5.
    McArthur KE, Collen MJ, Maton PN, Cherner JA, Howard JM, Gardner JD, Jensen RT. Omeprazole: Effective convenient therapy for Zollinger-Ellison syndrome. Gastroenterology 1985;88:939–944.PubMedGoogle Scholar
  6. 6.
    Carlsson E, Larsson H, Mattson H, Ryberg B, Sundell G. Pharmacology and toxicology of omeprazole—with special reference to the effect on the gastric mucosa. Scand J Gastroenterol 1986;21 (Suppl 118):31–38.CrossRefGoogle Scholar
  7. 7.
    Maton PN, McArthur KE, Wank SA, Slaff JI, Jensen RT, Gardner JD. Long term efficacy and safety of omeprazole in patients with Zollinger-Ellison syndrome. Gastroenterology 1986;90:1537.Google Scholar
  8. 8.
    Jensen RT, Doppman JL, Gardner JD. Gastrinoma. In: The Exocrine Pancreas: Biology, Pathobiology and Disease (Go VLW, Gardner JD, Brooks FP, Lebenthal E, DiMagno EP, Scheele GA, eds). New York: Raven Press, 1986, pp. 727–744.Google Scholar
  9. 9.
    Elder JB. Inhibition of acid and gastric carcinoids. Gut 1985;26:1279–1283.PubMedCrossRefGoogle Scholar
  10. 10.
    Larsson H, Carlsson E, Mattsson H, Lundell L, Sundler F, Sundell G, Wallmark B, Watanabe T, Hakanson R. Plasma gastrin and gastric enterochromaffin-like cell activation and proliferation. Studies with omeprazole and ranitidine in intact and antrectomized rats. Gastroenterology 1986;90:391–399.PubMedGoogle Scholar
  11. 11.
    Pounder RE, Sharma BK, Walt RP. Twenty-four hour intragastric acidity during treatment with oral omeprazole. Scand J Gastroenterol 1986;21(Suppl 118): 108–116.CrossRefGoogle Scholar
  12. 12.
    Reichlin S. Somatostatin. N Engl J Med 1983;309:1495–1501, 1556–1563.PubMedCrossRefGoogle Scholar
  13. 13.
    Maton PN, Gardner JD, Jensen RT. The use of the long-acting somatostatin analogue SMS 201–995 in patients with pancreatic islet cell tumors. Dig Dis Sci 1989;(in press).Google Scholar
  14. 14.
    Maton PN, O’Dorisio TM, Howe BA, McArthur KE, Howard JM, Cherner JA, Malarky WB, Collen MJ, Gardner JD, Jensen RT. Effect of long-acting somatostatin analogue (SMS 201–995) in a patient with pancreatic cholera. N Engl J Med 1985;312:17–21.PubMedCrossRefGoogle Scholar
  15. 15.
    Kane ME, O’Dorisio TM, Krejs GJ. Production of secretory diarrhea by intravenous infusion of vascoactive intestinal polypeptide. N Engl J Med 1983;309:1482–1485.PubMedCrossRefGoogle Scholar
  16. 16.
    Maton PN, O’Dorisio TM, O’Dorisio MS, Malarkey WB, Gower WJ Jr., Gardner JD, Jensen RT. Successful therapy of pancreatic cholera with the long acting somatostatin analogue SMS 201–995. Relation between plasma concentrations of drug and clinical and biochemical responses. Scand J Gastroenterol 1986;21(Suppl 119):181–186.CrossRefGoogle Scholar
  17. 17.
    Camisa C, O’Dorisio TM, Maceyko R, Mekhjian HS, Malarkey WB. Improvement of psoriasis with chronic use of somatostatin (SMS) analogue SMS 201–995. Clin Res 1987;35:637A.Google Scholar
  18. 18.
    Johnston DG, Davies RR, Turner SJ. Effects of somatostatin and SMS 201–995 on carbohydrate metabolism in normal man. Scand J Gastroenterol 1986;21(Suppl 119): 158–165.CrossRefGoogle Scholar
  19. 19.
    Gyr KE, Whitehouse I, Beglinger C, Kohler E, Dettwiler S, Fried M. Human pharmacological effects of SMS 201–995 on gastric secretion. Scand J Gastroenterol 1986;21(Suppl 119):96–102.CrossRefGoogle Scholar
  20. 20.
    Lamberts SWJ, Del Pozo E. Acute and long-term effects of SMS 201–995 in acromegaly. Scand J Gastroenterol 1986;21(Suppl 119): 141–148.CrossRefGoogle Scholar
  21. 21.
    Bonfils S, Ruszniewski P. Laucournet H, Costil V, Rene W, Mignon M. Long-term management of Zollinger-Ellison syndrome with SMS 201–995, a long-lasting somatostatin analog. Can J Physiol Pharm: Program of the 6th International Symposium on Gastrointestinal Hormone, Vancouver, Canada, July 6–10, 1986, p. 63.Google Scholar
  22. 22.
    Shepherd JJ, Senator GB. Regression of liver metastases in patients with gastrin-secreting tumor treated with SMS 201–995. Lancet 1986;2:574.PubMedCrossRefGoogle Scholar
  23. 23.
    Kvols LK, Buck M, Moertel CG, Schutt AJ, Rubin J, O’Connell MJ, Hahn RG. Treatment of metastatic islet cell carcinoma with a somatostatin analogue (SMS 201–995). Ann Intern Med 1987; 107:162–168.PubMedGoogle Scholar
  24. 24.
    Edwards CA, Cann PA, Read NW, Holdsworth CD. The effect of somatostatin analogue SMS 201–995 on fluid and electrolyte transport in a patient with secretory diarrhea. Scand J Gastroenterol 1986;21(Suppl 119):259–261.CrossRefGoogle Scholar
  25. 25.
    Krejs GJ, Orci LO, Conlon JM, Ravazzola M, Davis GR, Raskin P, Collins SM, McCarthy DM, Baetens D, Rubinstein A, Aldor TAM, Unger RH. Somatostatinoma syndrome: Biochemical, morphologic, and clinical features. N Engl J Med 1979;301:285–292.PubMedCrossRefGoogle Scholar
  26. 26.
    Wank SA, Doppman JL, Miller DL, Collen MJ, Maton PN, Vinayek R, Slaff JI, Norton JA, Gardner JD, Jensen RT. Prospective study of the ability of computed axial tomography to localize gastrinomas in patients with Zollinger-Ellison syndrome. Gastroenterology 1987;92:905–912.PubMedGoogle Scholar
  27. 27.
    Maton PN, Miller DL, Doppman JL, Collen MJ, Norton JA, Vinayek R, Slaff JE, Wank SA, Gardner JD, Jensen RT. Role of selective angiography in the management of patients with Zollinger-Ellison syndrome. Gastroenterology 1987;92:913–918.PubMedGoogle Scholar
  28. 28.
    Cherner JA, Doppman JL, Norton JA, Miller DL, Krudy AG, Raufman J-P, Collen MJ, Maton PN, Gardner JD, Jensen RT. Selective venous sampling for gastrin to localize gastrinomas. Ann Intern Med 1986;105:841–847.PubMedGoogle Scholar
  29. 29.
    Dunnink NR, Long JA Jr., Krudy A, Shanker TH, Doppman JL. Localizing insulinomas with combined radiographic techniques. Am J Roentgenol 1980; 135:747–752.Google Scholar
  30. 30.
    Cromack DT, Norton JA, Sigel B, Shawker TH, Doppman JL, Maton PN, Jensen RT. The use of high resolution intraoperative ultrasound to localize gastrinomas. An initial report of a prospective study. World J Surg 1987;11:648–652.PubMedCrossRefGoogle Scholar
  31. 31.
    Norton JA, Doppman JL, Collen MJ, Harmon JW, Maton PN, Gardner JD, Jensen RT. Prospective study of gastrinoma localization and resection in patients with Zollinger-Ellison syndrome. Ann Surg 1986;204:468–479.PubMedCrossRefGoogle Scholar
  32. 32.
    Roche A, Raisonnier A, Gillon-Savouret MC. Pancreatic venous sampling and arteriography in localizing insulinomas and gastrinomas: Procedure and results in 55 cases. Radiology 1982;145:621–627.PubMedGoogle Scholar
  33. 33.
    Comi RJ, Gorden P, Doppman JL, Norton JL. Insulinoma. In: The Exocrine Pancreas: Biology, Pathobiology and Diseases (Go VLW, Gardner JD, Brooks FP, Lebenthal E, DiMagno EP, Scheele GA, eds). New York: Raven Press, 1986, pp. 745–761.Google Scholar
  34. 34.
    Norton JA, Sugarbaker PH, Doppman JL, Wesley RA, Maton PN, Gardner JD, Jensen RT. Aggressive resection of metastatic disease in selected patients with malignant gastrinoma. Ann Surg 1986;203:352–359.PubMedCrossRefGoogle Scholar
  35. 35.
    Allison DJ. The nonsurgical management of metastatic endocrine tumours to the liver. In: Interventional Radiology (Wilkins RA, Viamonte M, eds). Oxford: Blackwell Scientific, 1982, pp. 191–208.Google Scholar
  36. 36.
    Moertel CG, Hanley JA, Johnson LA. Streptozotocin alone compared with streptozotocin plus fluorouracil in the treatment of advanced islet cell carcinoma. N Engl J Med 1980;303:1189–1194.PubMedCrossRefGoogle Scholar
  37. 37.
    von Schrenk T, Howard J, Doppman JL, Norton JA, Maton PN, Smith F, Vinayek R, Frucht H, Wank SA, Gardner JD, Jensen RT. Prospective study of chemotherapy in patients with metastatic gastrinoma. Gastroenterology 1988;94:1326–34.Google Scholar
  38. 38.
    Reubi JC. Somatostatin analogue inhibits chondrosarcoma and insulinoma tumor growth. Acta Endocrinol 1985;109:108–114.PubMedGoogle Scholar
  39. 39.
    Eriksson B, Oberg K, Aim G, Karlsson A, Lindqvist G, Andersson T, Wilander E, Wide L. Treatment of malignant endocrine pancreatic tumors with human leukocyte interferon. Lancet 1986;2:1307–1309.PubMedCrossRefGoogle Scholar

Copyright information

© Plenum Publishing Corporation 1989

Authors and Affiliations

  • Paul N. Maton
    • 1
  1. 1.Digestive Diseases Branch, National Institute of Diabetes and Digestive and Kidney DiseasesNational Institutes of HealthBethesdaUSA

Personalised recommendations